Status:
TERMINATED
ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial
Lead Sponsor:
The Medicines Company
Conditions:
Peripheral Endovascular Interventions
Bleeding
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective of the study is to test whether anticoagulation with bivalirudin results in fewer major bleeding complications compared with unfractionated heparin (UFH) in participants undergoi...
Eligibility Criteria
Inclusion
- Participants ≥ 18 years of age
- Must be undergoing one of the following PEI procedures:
- Carotid artery stenting
- Lower Extremity Interventions (LEI) for Critical Limb Ischemia
- LEI for claudication
- Provide written informed consent prior to any study-specific procedure being performed
Exclusion
- Any known contra-indication to the use of bivalirudin or UFH
- Acute limb ischemia
- Planned amputation regardless of the outcome of the PEI
- Dialysis dependent
- Weight less than 38 kg or more than 202 kg
- History of any bleeding diathesis or severe hematological disease
- History of intra-cranial: mass, aneurysm, arteriovenous malformation or hemorrhage
- Gastrointestinal or genitourinary bleeding within the 30 days prior to randomization
- Any surgery (excluding punch or shave skin biopsy) within the 30 days prior to randomization
- Concomitant percutaneous coronary intervention
- Any percutaneous coronary, endovascular, or structural heart disease procedure within 30 days prior to randomization
- International normalized ratio \>1.7 within 24 h prior to the index procedure
- Administration of therapeutic doses of UFH within 30 min prior to the index procedure (a low dose \[≤2000 U\] of heparin is permitted during the diagnostic angiogram prior to the intervention)
- Administration of enoxaparin within 8 h; other low molecular weight heparins or fondaparinux within 24 h; any oral anti-Xa or antithrombin agent within 48 h; or thrombolytics, glycoprotein inhibitors, or warfarin within 72 h prior to the index procedure
- Severe contrast allergy that cannot be pre-medicated
- Procedures performed by radial access when they are intended as the primary access site for the index procedure
- Known or suspected pregnant women or nursing mothers
- Previous enrollment in this study (MDCO-BIV-12-03)
- Participation in other investigational drug or device trials within 30 days prior to randomization
- Participants who, for any reason, are deemed by the investigator to be inappropriate for this study
Key Trial Info
Start Date :
September 24 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 16 2016
Estimated Enrollment :
732 Patients enrolled
Trial Details
Trial ID
NCT01913483
Start Date
September 24 2013
End Date
March 16 2016
Last Update
May 30 2017
Active Locations (39)
Enter a location and click search to find clinical trials sorted by distance.
1
Tri-Lakes Research
Hot Springs, Arkansas, United States, 71901
2
Stanford Hospital and Clinics
Stanford, California, United States, 94305-5407
3
Clearwater Cardiovascular and Interventional Consultants
Clearwater, Florida, United States, 33756
4
Florida Research Network
Gainesville, Florida, United States, 32605